BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 30442649)

  • 1. Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2017.
    Yu J; Petrie ID; Levy RH; Ragueneau-Majlessi I
    Drug Metab Dispos; 2019 Feb; 47(2):135-144. PubMed ID: 30442649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitors of Organic Anion-Transporting Polypeptides 1B1 and 1B3: Clinical Relevance and Regulatory Perspective.
    McFeely SJ; Ritchie TK; Yu J; Nordmark A; Berglund EG; Levy RH; Ragueneau-Majlessi I
    J Clin Pharmacol; 2020 Aug; 60(8):1087-1098. PubMed ID: 32196692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calibrating the In Vitro-In Vivo Correlation for OATP-Mediated Drug-Drug Interactions with Rosuvastatin Using Static and PBPK Models.
    Sane R; Cheung KWK; Kovács P; Farasyn T; Li R; Bui A; Musib L; Kis E; Plise E; Gáborik Z
    Drug Metab Dispos; 2020 Dec; 48(12):1264-1270. PubMed ID: 33037044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preincubation With Everolimus and Sirolimus Reduces Organic Anion-Transporting Polypeptide (OATP)1B1- and 1B3-Mediated Transport Independently of mTOR Kinase Inhibition: Implication in Assessing OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions.
    Farasyn T; Crowe A; Hatley O; Neuhoff S; Alam K; Kanyo J; Lam TT; Ding K; Yue W
    J Pharm Sci; 2019 Oct; 108(10):3443-3456. PubMed ID: 31047942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and Evaluation of Clinical Substrates of Organic Anion Transporting Polypeptides 1B1 and 1B3.
    McFeely SJ; Ritchie TK; Yu J; Nordmark A; Levy RH; Ragueneau-Majlessi I
    Clin Transl Sci; 2019 Jul; 12(4):379-387. PubMed ID: 30706983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of Clinical Drug-Drug Interactions of Elagolix, a Gonadotropin-Releasing Hormone Receptor Antagonist.
    Polepally AR; Ng JW; Salem AH; Dufek MB; Parikh A; Carter DC; Kamradt K; Mostafa NM; Shebley M
    J Clin Pharmacol; 2020 Dec; 60(12):1606-1616. PubMed ID: 33045114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Investigation of Coproporphyrins as Sensitive Biomarkers to Predict Mild to Strong OATP1B-Mediated Drug-Drug Interactions.
    Kunze A; Ediage EN; Dillen L; Monshouwer M; Snoeys J
    Clin Pharmacokinet; 2018 Dec; 57(12):1559-1570. PubMed ID: 29663259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Further Studies to Support the Use of Coproporphyrin I and III as Novel Clinical Biomarkers for Evaluating the Potential for Organic Anion Transporting Polypeptide 1B1 and OATP1B3 Inhibition.
    Shen H; Christopher L; Lai Y; Gong J; Kandoussi H; Garonzik S; Perera V; Garimella T; Humphreys WG
    Drug Metab Dispos; 2018 Aug; 46(8):1075-1082. PubMed ID: 29777022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alteration in the Plasma Concentrations of Endogenous Organic Anion-Transporting Polypeptide 1B Biomarkers in Patients with Non-Small Cell Lung Cancer Treated with Paclitaxel.
    Mori D; Ishida H; Mizuno T; Kusumoto S; Kondo Y; Izumi S; Nakata G; Nozaki Y; Maeda K; Sasaki Y; Fujita KI; Kusuhara H
    Drug Metab Dispos; 2020 May; 48(5):387-394. PubMed ID: 32114508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of Clinically Relevant Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration Between 2013 and 2016.
    Yu J; Zhou Z; Tay-Sontheimer J; Levy RH; Ragueneau-Majlessi I
    Drug Metab Dispos; 2018 Jun; 46(6):835-845. PubMed ID: 29572333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GDC-0810 Pharmacokinetics and Transporter-Mediated Drug Interaction Evaluation with an Endogenous Biomarker in the First-in-Human, Dose Escalation Study.
    Cheung KWK; Yoshida K; Cheeti S; Chen B; Morley R; Chan IT; Sahasranaman S; Liu L
    Drug Metab Dispos; 2019 Sep; 47(9):966-973. PubMed ID: 31266752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of OATP transporter-mediated drug-drug interaction using physiologically-based pharmacokinetic (PBPK) modeling - a case example.
    Chen Y; Zhu R; Ma F; Mao J; Chen EC; Choo EF; Sahasranaman S; Liu L
    Biopharm Drug Dispos; 2018 Nov; 39(9):420-430. PubMed ID: 30335192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1.
    Kimoto E; Vourvahis M; Scialis RJ; Eng H; Rodrigues AD; Varma MVS
    Drug Metab Dispos; 2019 May; 47(5):493-503. PubMed ID: 30862625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of novel cell-impermeant fluorescent substrates for testing the function and drug interaction of Organic Anion-Transporting Polypeptides, OATP1B1/1B3 and 2B1.
    Patik I; Székely V; Német O; Szepesi Á; Kucsma N; Várady G; Szakács G; Bakos É; Özvegy-Laczka C
    Sci Rep; 2018 Feb; 8(1):2630. PubMed ID: 29422623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions.
    Hanke N; Gómez-Mantilla JD; Ishiguro N; Stopfer P; Nock V
    Pharm Res; 2021 Oct; 38(10):1645-1661. PubMed ID: 34664206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of Weak Organic Anion-Transporting Polypeptide 1B Inhibition by Probenecid with Plasma-Based Coproporphyrin in Humans.
    Zhang Y; Holenarsipur VK; Kandoussi H; Zeng J; Mariappan TT; Sinz M; Shen H
    Drug Metab Dispos; 2020 Oct; 48(10):841-848. PubMed ID: 32723847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with proteasome inhibitor bortezomib decreases organic anion transporting polypeptide (OATP) 1B3-mediated transport in a substrate-dependent manner.
    Alam K; Farasyn T; Crowe A; Ding K; Yue W
    PLoS One; 2017; 12(11):e0186924. PubMed ID: 29107984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms and Predictions of Drug-Drug Interactions of the Hepatitis C Virus Three Direct-Acting Antiviral Regimen: Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir.
    Shebley M; Liu J; Kavetskaia O; Sydor J; de Morais SM; Fischer V; Nijsen MJMA; Bow DAJ
    Drug Metab Dispos; 2017 Jul; 45(7):755-764. PubMed ID: 28483778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the Effects of Repeat-Dose Dabrafenib on the Single-Dose Pharmacokinetics of Rosuvastatin (OATP1B1/1B3 Substrate) and Midazolam (CYP3A4 Substrate).
    Nebot N; Won CS; Moreno V; Muñoz-Couselo E; Lee DY; Gasal E; Bouillaud E
    Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1054-1063. PubMed ID: 33932130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strong Pharmacokinetic Drug-Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2021: Mechanisms and Clinical Implications.
    Yu J; Wang Y; Ragueneau-Majlessi I
    Clin Ther; 2022 Nov; 44(11):1536-1544. PubMed ID: 36210218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.